Caitong International Asset Management
ESPR icon

Caitong International Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Caitong International Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.2K Buy
14,620
+14,581
+37,387% +$40.8K 0.01% 741
2026
Q1 		$107 Sell
39
-36,705
-100% -$116K ﹤0.01% 1958
2025
Q4 		$136K Buy
36,744
+5,492
+18% +$17.7K 0.03% 315
2025
Q3 		$82.8K Buy
31,252
+31,175
+40,487% +$60.3K 0.06% 206
2025
Q2 		$76 Sell
77
-2,795
-97% -$2.8K ﹤0.01% 1854
2025
Q1 		$4.14K Sell
2,872
-2,566
-47% -$4.73K ﹤0.01% 1077
2024
Q4 		$12K Buy
+5,438
New +$12.7K 0.01% 918

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
ODDO BHF Asset Management
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Caitong International Asset Management's ESPR Position: Q2 2026 in Review

Caitong International Asset Management increased its Esperion Therapeutics (ESPR) stake by 37,387% in Q2 2026, buying an estimated $40.8K and bringing the position to 14,620 shares worth $46.2K. The position accounts for 0.01% of the portfolio, ranked #741.

Caitong International Asset Management first reported a position in ESPR in Q4 2024 and has held it in 7 quarters since. The position peaked at $136K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Caitong International Asset Management held 14,620 shares of Esperion Therapeutics worth $46.2K as of Q2 2026.
  • Caitong International Asset Management bought 14,581 Esperion Therapeutics shares in Q2 2026, an estimated $40.8K.
  • Esperion Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #741 holding.
  • Caitong International Asset Management first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Caitong International Asset Management's Esperion Therapeutics position peaked at $136K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.